MT1B

Across TCGA pan-cancer cohorts, MT1B RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated MT1B data layer compared with 2 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MT1B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MT1B expression acts as an unfavorable survival marker, although some lineages such as CESC and PRAD show a favorable association.

STAD, BLCA, and LGG are the cancer types where MT1B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.530	0.754	.002	52	view →
BLCA	OS	Tertile	IV	0.440	0.632	.023	36	view →
LGG	OS	Tertile	All	0.372	0.543	.003	33	view →
CESC	OS	Tertile	III,IV	0.930	0.690	.030	30	view →
HNSC	OS	Tertile	All	0.589	0.725	.007	27	view →
KIRC	OS	Tertile	All	0.805	0.899	.033	24	view →
PRAD	DFS	Tertile	All	0.846	0.682	<.001	18	view →
TGCT	DFS	Quartile	All	0.726	0.877	.031	14	view →
THCA	DFS	Quartile	II,III,IV	0.863	0.687	.037	11	view →
LUSC	OS	Tertile	All	0.549	0.683	.023	9	view →
PCPG	OS	Tertile	All	0.888	1.000	.002	9	view →
OV	OS	Median	III,IV	0.648	0.704	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

MT1B–STAD (DFS)

Open the STAD breakdown →